Search the Newsreel

B. Riley Highlights Top Education Stocks Amid Sector Challenges

B. Riley has updated its outlook on key education stocks, maintaining positive stances on Phoenix Education Partners (PXED), American Public Education Inc. (APEI), and Universal Technical Institute Inc. (UTI). Despite sector challenges, the firm adjusted price targets for PXED, citing strong cash flow and …

B. Riley Adjusts Price Target on ADTRAN to $21 From $23, Maintains Buy Rating

B. Riley has adjusted its price target for ADTRAN (ADTN) to $21 from $23, while reaffirming a Buy rating on the stock. This revision comes as part of their ongoing analysis of the company.

Conduent stock trades steadily as digital services group works through turnaround and cost actions

Conduent Inc. (CNDT) stock reflects a gradual turnaround story as the company navigates past revenue declines, cost-cutting measures, and efforts to expand in transaction-heavy digital services. The article details Conduent's strategic focus on cost reduction, portfolio discipline, and technology investments to stabilize revenue and …

B Riley names top semiconductor capital equipment stocks

B Riley has highlighted key investment opportunities in the semiconductor capital equipment sector, particularly in back-end and OSAT sub-sectors, driven by increasing AI demand and advanced packaging investments. The firm identifies Cohu (COHU), Camtek (CAMT), Amkor Technology (AMKR), and Kulicke and Soffa Industries (KLIC) …

AGMB Initiated by B. Riley Securities -- Price Target Set at $34

B. Riley Securities analyst William Woods has initiated coverage on AgomAb Therapeutics (AGMB) with a "Buy" rating and a $34 price target. Despite a positive outlook due to its focus on developing innovative therapies for chronic fibrotic diseases, AGMB has a low GF Score™ …

ADTRAN (NASDAQ:ADTN) Receives Buy Rating from B. Riley Financial

B. Riley Financial reiterated a "buy" rating for ADTRAN (NASDAQ:ADTN), setting a $21 price target, which implies over 100% upside, despite a reduction from their previous $23 target. Analyst sentiment for ADTRAN remains mixed but generally positive, with a consensus "Moderate Buy" rating and …

B. Riley Cuts Price Target on Amkor Technology to $75 From $90, Keeps Neutral Rating

B. Riley has revised its price target for Amkor Technology, Inc. (AMKR) downwards to $75 from its previous $90 target, while maintaining a Neutral rating on the stock. This adjustment comes despite a recent uptick in Amkor's stock following a partnership announcement with Taiwan …

Stifel: Q2 Earnings Snapshot

The article "Stifel: Q2 Earnings Snapshot" is a placeholder or an article with missing content. It currently contains no substantive information regarding Stifel's Q2 earnings or any other financial data, other than stating its title.

Stifel Financial beats estimates on investment banking strength By Investing.com

Stifel Financial Corp. (NYSE:SF) reported strong second-quarter results, surpassing analyst estimates with adjusted earnings of $1.42 per share and net revenues of $1.45 billion. This performance was largely driven by a significant 42% year-over-year surge in investment banking revenues, coupled with growth in asset …

This Pharmaceutical Stock is a Top Pick at B. Riley By Investing.com

B. Riley has reiterated its Buy rating on Ovid Therapeutics, Inc., designating it as a top pick in the pharmaceutical sector. The firm highlights Ovid's compelling risk-reward profile despite significant year-to-date gains and points to multiple catalysts anticipated between late 2026 and early 2027 …

EQS-Adhoc: Dürr Aktiengesellschaft: Effizienzsteigerung bei BBS Automation, vorläufige Zahlen Q2 2026 - boerse.de

(RILYT) Price Dynamics and Execution-Aware Positioning

This article analyzes the price dynamics of B. Riley Financial Inc. 6.00% Senior Notes Due 2028 (NASDAQ: RILYT), highlighting weak near-term sentiment but potential long-term strength. It outlines three AI-generated institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. …

Why (RILYG) Price Action Is Critical for Tactical Trading

This article provides a critical analysis of B. Riley Financial Inc. 5.00% Senior Notes Due 2026 (RILYG) for tactical trading, identifying a neutral near and mid-term outlook with a potential long-term positive bias. It highlights a mid-channel oscillation pattern and offers detailed institutional trading …

The Technical Signals Behind (RILYN) That Institutions Follow

This article analyzes the technical signals for B. Riley Financial Inc. 6.50% Senior Notes Due 2026 (NASDAQ: RILYN). It identifies a neutral near and mid-term outlook with a positive long-term bias, noting a mid-channel oscillation pattern. The report provides three AI-generated trading strategies (Position, …

B. Riley raises AST SpaceMobile to Buy rating, citing valuation opportunity after stock's sharp pullback from May highs

B. Riley upgraded AST SpaceMobile (ASTS) to Buy from Neutral, maintaining an $85 price target, despite a 44% decline in shares over six months. The upgrade follows AST SpaceMobile's $1 billion convertible senior notes offering, which analyst Mike Crawford believes provides sufficient capital for …

Rubico Terminates $30 Million Equity Facility With B. Riley

Rubicon Technologies terminated its $30 million equity line of credit with B. Riley Principal Capital, citing the facility's misalignment with its current capital plan and an advantageous market position for future financing. The company plans to continue pursuing non-dilutive and strategic financing alternatives.

B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

B. Riley Financial has increased its price target for Trevi Therapeutics (NASDAQ:TRVI) to $31 from $21, maintaining a "buy" rating and suggesting a 64% upside. While other analysts have a "Moderate Buy" consensus with an average target of $23.80, Weiss Ratings reiterated a "sell" …

TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00

B. Riley Securities has maintained a Buy rating for Trevi Therapeutics (TRVI) and increased its price target to $31.00 from $21.00, signaling strong confidence in the company's potential, especially for its Haduvio therapy. Despite this bullish analyst outlook, Trevi Therapeutics faces financial challenges with …

B. Riley keeps Hut 8 at Buy after second $9.8 billion Beacon Point lease

B. Riley Securities has maintained its Buy rating and $130 price target for Hut 8 after the company signed a second 15-year lease valued at $9.8 billion for 352 MW of IT capacity at its Beacon Point campus in Texas. This triple-net lease for …

CNDT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock Reaction - EPS Surprise History

ASTS Upgraded by B. Riley Securities -- Rating Raised to Buy

AST SpaceMobile (ASTS) has been upgraded from a "Neutral" to a "Buy" rating by B. Riley Securities, with the price target maintained at $85.00. While GuruFocus indicates the stock is significantly undervalued with a GF Value™ of $488.29 against a current price of $57.80, …

AST SpaceMobile Shares Rise After B. Riley Upgrade

This article reports on AST SpaceMobile (ASTS) shares rising following an upgrade from B. Riley. The upgrade reflects a positive outlook for the company's future prospects.

CNK Maintained by B. Riley Securities -- Price Target Lowered to $35

B. Riley Securities has maintained a Neutral rating on Cinemark Holdings (CNK) but lowered its price target to $35.00 from $36.00. While GuruFocus suggests the stock is undervalued by 4.8% at $30.27, mixed analyst sentiment and recent insider selling of $4.4 million warrant caution …

AST SpaceMobile surges as B. Riley raises on valuation after selloff (ASTS:NASDAQ)

AST SpaceMobile (ASTS) saw its stock rise by 7.8% on Friday after B. Riley upgraded the company's rating to Buy from Neutral, setting an $85 price target. This upgrade follows a 44% slump in the shares over the past six months, with B. Riley …

Cinemark (NYSE:CNK) Price Target Cut to $35.00 by Analysts at B. Riley Financial

B. Riley Financial has reduced its price target for Cinemark (NYSE:CNK) to $35.00 from $36.00, maintaining a "neutral" rating, which implies a potential 15% upside. This adjustment comes amidst mixed analyst sentiment, with Goldman Sachs upgrading the stock to neutral and Zacks downgrading it …

B.Riley upgrades AST Spacemobile stock rating to Buy on funding

B.Riley upgraded AST Spacemobile (NASDAQ:ASTS) from Neutral to Buy, maintaining a price target of $85.00, following the company's successful pricing of $1 billion in convertible senior notes. Despite a 44% decline in share price since a previous downgrade, the company's strong liquidity and progress …

Conduent (NASDAQ: CNDT) director gets 20,353 deferred stock units

Conduent Inc. director Letier A. Scott was awarded 20,353 Deferred Stock Units (DSUs) on July 15, 2026, valued at $1.56 per share. These DSUs convert to common stock upon separation of service, increasing Scott's direct holdings to 737,298 shares. The transaction is a compensation-related …

B.Riley cuts Bitmine Immersion stock price target on staking miss

B.Riley has lowered its price target for Bitmine Immersion Technologies (OTC:BMNR) stock from $33 to $25, while maintaining a Buy rating, following the company's fiscal third-quarter 2026 results which saw staking revenue miss estimates. The shortfall was attributed to the pace of Ethereum staking …

Stifel CEO to Review Second-Quarter Results in July 22 Webcast

Stifel Financial Corp. (NYSE: SF) will release its second-quarter 2026 financial results before market open on July 22, 2026. Chairman and CEO Ronald J. Kruszewski will host a conference call at 9:30 a.m. Eastern time to discuss the results. The call will be accessible …

Stifel Financial Corp. to Announce Second Quarter 2026 Financial Results on July 22

Stifel Financial Corp. will release its second-quarter financial results on July 22, 2026, before the market opens, followed by a conference call at 9:30 a.m. Eastern Time. Chairman and CEO Ronald J. Kruszewski will lead the call, which will be accessible via dial-in and …

Conduent Named a Leader in 2026 NelsonHall Benefits Administration NEAT Evaluation for the Ninth Year Running

Conduent (Nasdaq: CNDT) has been named a Leader in the 2026 NelsonHall Benefits Administration NEAT Evaluation for the ninth consecutive year, recognized for its innovation and expertise in simplifying benefits administration. The report highlights Conduent's Life@Work Connect Experience platform, which integrates AI-powered tools like …

B. Riley Lifts PT on Angel Studios (ANGX) – Here’s Why

B. Riley has increased its price target for Angel Studios (ANGX) to $8 from $7, maintaining a Buy rating. This adjustment is based on higher near-term estimates, including increased fiscal Q2 paying Guild members and the anticipated positive impact of the upcoming film "Young …

BRC Group Holdings 2026 Notes (RILYG) Edge Higher: Modest Gains Amid Credit Stability - Watchlist Stock Ideas

B. Riley Financial, Inc. Q1 2026 Earnings Call Summary